Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports

Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports

The advent of intra-nasal esketamine (ESK), one of the first so called <i>fast-acting antidepressant</i>, promises to revolutionize the management of treatment resistant depression (TRD). This NMDA receptor antagonist has proven to be rapidly effective in the short- and medium-term cours...

Full description

Bibliographic Details
Main Authors: Matteo Marcatili, Riccardo Borgonovo, Noemi Cimminiello, Ranieri Domenico Cornaggia, Giulia Casati, Cristian Pellicioli, Laura Maggioni, Federico Motta, Chiara Redaelli, Luisa Ledda, Federico Emanuele Pozzi, Michaela Krivosova, Jessica Pagano, Roberto Nava, Fabrizia Colmegna, Antonios Dakanalis, Alice Caldiroli, Enrico Capuzzi, Beatrice Benatti, Bernardo Dell’Osso, Francesca Bertola, Nicoletta Villa, Alberto Piperno, Silvia Ippolito, Ildebrando Appollonio, Carlo Sala, Luciano Conti, Massimo Clerici
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Journal of Personalized Medicine
Subjects:
treatment resistant depression (TRD)
difficult to treat depression (DTD)
minocycline
esketamine
ketamine
pharmacogenetics
Online Access:https://www.mdpi.com/2075-4426/12/9/1524

Internet

https://www.mdpi.com/2075-4426/12/9/1524

Similar Items